PRCT
What one share of PROCEPT BioRobotics holds
Surgical and Medical Instruments and Apparatus
We are a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. We develop, manufacture and sell the AquaBeam Robotic System and HYDROS Robotic System, which are advanced, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH.
PROCEPT BioRobotics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $5.99 |
|---|---|
| Profit | −$1.95 |
| Capex (buildings and equipment) | $0.19 |
| Free cash flow | −$1.51 |
| Cash and investments | $3.98 |
| Debt | $0.90 |
| Book value | $5.94 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | $2.11 | −$14.47 | $0.06 | −$13.26 | — | −$38.81 |
| 2021 | $2.09 | −$3.63 | $0.04 | −$3.51 | — | — |
| 2022 | $1.69 | −$1.96 | $0.06 | −$1.87 | — | $4.40 |
| 2023 | $2.88 | −$2.24 | $0.53 | −$2.82 | — | $5.53 |
| 2024 | $4.31 | −$1.75 | $0.08 | −$1.99 | — | $7.35 |
| 2025 | $5.55 | −$1.72 | $0.17 | −$1.05 | — | $6.50 |